US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

TransCode Therapeutics, Inc. - Common Stock (NQ:RNAZ)

1.570 +0.025 (+1.62%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TransCode Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered ↗
TransCode Therapeutics shares are trading lower by 40.6% during Monday's session. The company disclosed plans for a potential reverse stock split in an open letter to its shareholders. 
Via Benzinga
News headline image
Squarespace (SQSP) Stock Climbs 13% on $6.9 Billion Deal to Go Private ↗
Squarespace stock is up on Monday as SQSP investors react to a $6.9 billion deal to take the business management company private. 
Via InvestorPlace
News headline image
Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today? ↗
TransCode Therapeutics stock is down on Monday after the company announced plans for a shareholder meeting for RNAZ investors. 
Via InvestorPlace
News headline image
Looking Into TransCode Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
TransCode Therapeutics Open Letter to Shareholders
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
News headline image
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Reports 2023 Results; Provides Business Update
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
Medical oncologist brings over 25 years of industry experience to lead Clinical Development Strategy 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
Highlights TTX-MC138’s Path from Target Discovery to the Clinic 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Nextracker Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗
Shares of Nextracker Inc. (NASDAQ: NXT) rose sharply during today’s pre-market trading after the company reported better-than-expected thi 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time to get into the biggest pre-market stock movers as we check out all of the hottest news happening on Thursday morning! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
Project to test combination of TransCode’s proprietary TTX delivery platform and Debiopharm’s drug delivery technologies 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan... 
Via Benzinga
News headline image
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A First-in-Class Compound Designed to Treat Metastatic... 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >